Cargando…
The efficacy of addition of Tenofovir Disoproxil Fumarate to Peg-IFNα-2b is superior to the addition of Entecavir in HBeAg positive CHB patients with a poor response after 12 weeks of Peg-IFNα-2b treatment alone
Background: There are limited data regarding the efficacy of addition of entecavir (ETV) or tenofovir disoproxil fumarate (TDF) to Peg-IFNα-2b in HBeAg positive chronic hepatitis B (CHB) patients without early response to Peg-IFNα-2b. In this study, we aimed to evaluate the efficacy of ETV and TDF i...
Autores principales: | Lin, Sheng, Fu, Ya, Wu, Wennan, Chen, Tianbin, Chen, Ningdai, Xun, Zhen, Liu, Can, Ou, Qishui, Zeng, Yongbin, Huang, Huanhuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330670/ https://www.ncbi.nlm.nih.gov/pubmed/32624702 http://dx.doi.org/10.7150/ijms.45658 |
Ejemplares similares
-
Immune drivers of HBsAg loss in HBeAg-negative CHB patients after stopping nucleotide analog and administration of Peg-IFN
por: Islam, Mojahidul, et al.
Publicado: (2023) -
Using machine learning models to predict HBeAg seroconversion in CHB patients receiving pegylated interferon‐α monotherapy
por: Shang, Hongyan, et al.
Publicado: (2022) -
The relationship between the clearance of HBsAg and the remodeling of B cell subsets in CHB patients treated with Peg-IFN-α
por: Wu, Ze-Qian, et al.
Publicado: (2021) -
Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial
por: Xu, Yan, et al.
Publicado: (2017) -
Triple motif proteins 19 and 38 correlated with treatment responses and HBsAg clearance in HBeAg-negative chronic hepatitis B patients during peg-IFN-α therapy
por: Luo, Haiying, et al.
Publicado: (2023)